PNU 159548

Known as: PNU-159548 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1999-2005
012319992005

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
The effectiveness of the alkycycline 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548… (More)
Is this relevant?
2003
2003
A haematotoxicity model was proposed by Parchment in 1998 to predict the maximum-tolerated dose (MTD) in humans of… (More)
Is this relevant?
2002
2002
PNU-159548 (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin) is the lead compound of a novel class of… (More)
Is this relevant?
2001
2001
Purpose: PNU-159548 (4-demethoxy-3'-deamino-3'aziridinyl-4'-methylsulphonyl-daunorubicin), a derivative of the anticancer… (More)
Is this relevant?
2001
2001
4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548) belongs to a novel class of antitumor compounds… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2001
2001
The activity of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a new alkycycline with high… (More)
Is this relevant?
1999
1999
A selective, sensitive and fully automated column-switching LC system using direct injection of human plasma followed by mass… (More)
Is this relevant?